270 related articles for article (PubMed ID: 26585155)
1. Detection of Endogenous Selective Estrogen Receptor Modulators such as 27-Hydroxycholesterol.
Nelson ER
Methods Mol Biol; 2016; 1366():431-443. PubMed ID: 26585155
[TBL] [Abstract][Full Text] [Related]
2. 27-hydroxycholesterol is an endogenous selective estrogen receptor modulator.
DuSell CD; Umetani M; Shaul PW; Mangelsdorf DJ; McDonnell DP
Mol Endocrinol; 2008 Jan; 22(1):65-77. PubMed ID: 17872378
[TBL] [Abstract][Full Text] [Related]
3. 27-Hydroxycholesterol, an endogenous selective estrogen receptor modulator.
He S; Nelson ER
Maturitas; 2017 Oct; 104():29-35. PubMed ID: 28923174
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor.
Levenson AS; Svoboda KM; Pease KM; Kaiser SA; Chen B; Simons LA; Jovanovic BD; Dyck PA; Jordan VC
Cancer Res; 2002 Aug; 62(15):4419-26. PubMed ID: 12154049
[TBL] [Abstract][Full Text] [Related]
5. The cholesterol metabolite 27-hydroxycholesterol regulates p53 activity and increases cell proliferation via MDM2 in breast cancer cells.
Raza S; Ohm JE; Dhasarathy A; Schommer J; Roche C; Hammer KD; Ghribi O
Mol Cell Biochem; 2015 Dec; 410(1-2):187-95. PubMed ID: 26350565
[TBL] [Abstract][Full Text] [Related]
6. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance.
Lewis JS; Jordan VC
Mutat Res; 2005 Dec; 591(1-2):247-63. PubMed ID: 16083919
[TBL] [Abstract][Full Text] [Related]
7. Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta3 on estrogenic ligands with different intrinsic activity.
Reiter R; Oh AS; Wellstein A; Riegel AT
Oncogene; 2004 Jan; 23(2):403-9. PubMed ID: 14691461
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms of selective estrogen receptor modulator (SERM) action.
Dutertre M; Smith CL
J Pharmacol Exp Ther; 2000 Nov; 295(2):431-7. PubMed ID: 11046073
[TBL] [Abstract][Full Text] [Related]
9. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer.
Jordan VC; O'Malley BW
J Clin Oncol; 2007 Dec; 25(36):5815-24. PubMed ID: 17893378
[TBL] [Abstract][Full Text] [Related]
10. Differential estradiol and selective estrogen receptor modulator (SERM) regulation of Keratin 13 gene expression and its underlying mechanism in breast cancer cells.
Sheng S; Barnett DH; Katzenellenbogen BS
Mol Cell Endocrinol; 2008 Dec; 296(1-2):1-9. PubMed ID: 18951949
[TBL] [Abstract][Full Text] [Related]
11. From empirical to mechanism-based discovery of clinically useful Selective Estrogen Receptor Modulators (SERMs).
Wardell SE; Nelson ER; McDonnell DP
Steroids; 2014 Nov; 90():30-8. PubMed ID: 25084324
[TBL] [Abstract][Full Text] [Related]
12. NJK14013, a novel synthetic estrogen receptor-α agonist, exhibits estrogen receptor-independent, tumor cell-specific cytotoxicity.
Kim HI; Kim T; Kim JE; Lee J; Heo J; Lee NR; Kim NJ; Inn KS
Int J Oncol; 2015 Jul; 47(1):280-6. PubMed ID: 25964080
[TBL] [Abstract][Full Text] [Related]
13. Acquired resistance to selective estrogen receptor modulators (SERMs) in clinical practice (tamoxifen & raloxifene) by selection pressure in breast cancer cell populations.
Fan P; Craig Jordan V
Steroids; 2014 Nov; 90():44-52. PubMed ID: 24930824
[TBL] [Abstract][Full Text] [Related]
14. Development of an ER action indicator mouse for the study of estrogens, selective ER modulators (SERMs), and Xenobiotics.
Nagel SC; Hagelbarger JL; McDonnell DP
Endocrinology; 2001 Nov; 142(11):4721-8. PubMed ID: 11606437
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens.
Chang KC; Wang Y; Bodine PV; Nagpal S; Komm BS
J Steroid Biochem Mol Biol; 2010 Jan; 118(1-2):117-24. PubMed ID: 19914376
[TBL] [Abstract][Full Text] [Related]
16. Research resource: Transcriptional profiling in a cellular model of breast cancer reveals functional and mechanistic differences between clinically relevant SERM and between SERM/estrogen complexes.
Wardell SE; Kazmin D; McDonnell DP
Mol Endocrinol; 2012 Jul; 26(7):1235-48. PubMed ID: 22570330
[TBL] [Abstract][Full Text] [Related]
17. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC
Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412
[TBL] [Abstract][Full Text] [Related]
18. Selective estrogen receptor modulators: an update on recent clinical findings.
Shelly W; Draper MW; Krishnan V; Wong M; Jaffe RB
Obstet Gynecol Surv; 2008 Mar; 63(3):163-81. PubMed ID: 18279543
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic targeting in the estrogen receptor hormonal pathway.
Katzenellenbogen BS; Frasor J
Semin Oncol; 2004 Feb; 31(1 Suppl 3):28-38. PubMed ID: 15052541
[TBL] [Abstract][Full Text] [Related]
20. Molecular identification of potential selective estrogen receptor modulator (SERM) like properties of phytoestrogens in the human breast cancer cell line MCF-7.
Diel P; Olff S; Schmidt S; Michna H
Planta Med; 2001 Aug; 67(6):510-4. PubMed ID: 11509969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
